MedTrace Logo

Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma

NCT03722355 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 712

Last updated 2019-11-12

No results posted yet for this study

Summary

Hyperfractionated radiation therapy (RT) to 72.0 Gy with BCNU will be compared to conventional radiation therapy to 60.0 Gy with BCNU to determine if hyperfractionated RT can improve the median survival time of adults with supratentorial malignant gliomas.

Conditions

Interventions

RADIATION

Conventional RT

Radiation therapy

RADIATION

Hyperfractionated RT

Radiation therapy

DRUG

Carmustine

Chemotherapy

Sponsors & Collaborators

  • Radiation Therapy Oncology Group

    lead NETWORK

Principal Investigators

  • Walter J Curran, Jr., MD · Radiation Therapy Oncology Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1990-11-09
Primary Completion
1994-03-15
Completion
2002-10-18

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03722355 on ClinicalTrials.gov